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1. Introduction 
Griseofulvin, an antifungic metabolite produced 
by several species of Penicillium [ 1 ], is widely used in 
human and animal therapy [2]. Its mechanism of 
action remained puzzling for along time [3]. Recently 
it has been shown that griseofulvin i hibits the polym- 
erization of purified brain tubulin [4,5]. Although 
this property may account for its in vivo effects, this 
result does not allow to rule out the hypothesis that 
microtubule proteins may not be the main target of 
this drug [6]. In order to check this possibility, several 
griseofulvin derivatives exhibiting alower or a higher 
activity than griseofulvin, were synthesized. Their 
in vivo effects were studied on a mouse leukemia cell 
line (L1210) and on a Myxomycete (Physarum). Their 
in vitro action was studied by monitoring the induced 
aggregation and the inhibition of polymerization f
purified brain mammalian microtubule proteins [4,5]. 
It was found that the in vitro activities of the various 
griseofulvin derivatives were in correlation with their 
in vivo activities uggesting that microtubule proteins 
do represent the pharmacological t rget ofgriseofulvin. 
2. Materials and methods 
2.1. Griseofulvin derivatives (fig.I) 
Griseofulvin was a gift from Imperials Chemical 
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Fig.1. Structure of griseofulvin derivatives. (a) Griseofulvin; 
Co) 2'-(2qodoethoxy)griseofulvin; (c) 2'-an~inogriseofulvin; 
(d) griseofulvie acid (enol form); (e) isogriseofulvin. 
Industries. The other derivatives were synthesized as 
in [7-9] .  They were dissolved in 1% final dimethyl 
sulfoxide for the in vivo studies. 
2.2. Leukemia cell culture 
Leukemia mouse cells (L1210) were grown in 
absence of mycoplasma, t37°(2 in a liquid defined 
medium (RPMI 1640 Gibco) supplemented with 10% 
horse serum, 60 plVl 2-mercaptoethanol, 2 mM 
L-glutamine, 50/ag/ml of streptomycin a d 200 U/ml 
penicillin [ 10]. Exponential growing cultures were 
used (2 X l0 s cells/ml). Cells were harvested 12 h and 
24 h after drug addition, treated at 37°C with 0.5 M 
potassium chloride and fixed successively during 
15 min and 30 min in acetic acid, ethanol (3 : 1) at 
0°C. Nuclei were spread on microscopic slides, stained 
with hemalun-eosin a d mounted in balsam. The nor. 
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mal nuclear diameter was 12-15/am. Nuclei having a 
diameter equal or lower than 6/am were recorded as 
micronuclei. Nuclei which were not spherical, but 
which showed a bud on their surface were recorded as 
'budding' nuclei. 
2.3. Physarum culture 
Physarum polycephalum icroplasmodia (strain 
CL) were grown in liquid defined medium I [11] at 
27°C under constant shaking (100 rev/min). Growth 
was followed by monitoring the variations of A 546 nm. 
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2.4. Preparation of brain microtubule proteins 
Microtubule proteins were purified from fresh 
sheep brains by 2 cycles of assembly in the presence 
of 4 M glycerol at 37°C and disassembly at 0°C [12]. 
Depolymerized material was kept at -30°C in 50% 
glycerol. Immediately before use, another cycle of 
assembly disassembly was performed. The last pellet 
was resuspended in 0.1 M PIPES, 2 mM EGTA, 
1 mM MgC12 and 0.5 mM GTP with protein conc. 
3 mg/ml. In the absence and in the presence of the 
drugs, protein aggregation (13°C) and tubulin polym- 
erization (37°C) were monitored at 400 nm [13] 
with a spectrophotometer (Beckman Acta III) and 
checked by electron microscopy. Drugs were dis- 
solved in 4% final dimethylformamide. At this con- 
centration the solvent has no effect neither on pro- 
tein aggregation nor on tubulin polymerization. 
3. Results 
3.1. In vitro aggregation fmicrotubule proteins 
The addition of griseofulvin into a cold solution of 
tubulin prepared as in [12] induces a very rapid 
increase in turbidity due to the aggregation of micro- 
tubule proteins [4,5,14]. This turbidity increase 
followed at 13°C reached a plateau, the level of which 
was measured 10 min after drug addition. These 
values were used to determine the highest drug con- 
centration (H13) unable to induce protein aggregation 
(fig.2a). The various griseofulvin derivatives studied 
differ with their ability to induce microtubule protein 
aggregation (table 1). Isogriseofulvin was slightly less 
active than griseofulvin. 2'-Aminogriseofulvin a d 
griseofulvic acid were 20 and 50 times less active than 
griseofulvin, although 2'-(2-iodoethoxy) griseofulvin 
was 3 times more active, 
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Fig.2. In vitro effects of griseofulvin derivatives on mammalian 
microtubule proteins. For each compound, the best curve 
fitting the experimental values was calculated by the method 
of the least squares. (a) Aggregation of microtubule proteins 
at 13°C. The plateau values of the increases in turbidity at 
400 nm were recorded according to drug concentrations. 
(b) Inhibition of tubulin polymerization at 37°C. (~r) 
2'-(2qodoethoxy)griseofulvin; (e) griseofulvin; (*) isogriseo- 
fulvin; (.) 2'-aminogriseofulvin; (.) griseofulvie acid. Drug 
concentrations are expressed in#M. 
3.2. In vitro inhibition of microtubule polymerization 
When a solution of tubulin is shifted from 13-3 7 ° C, 
microtubule polymerization takes place [12,13]. In 
the presence of griseofulvin, a strong inhibition of  
the polymerization process is observed [4,5]. In order 
to compare the action of the various griseofulvin 
derivatives, the percentage of inhibition was calculated 
for each drug concentration. These values were then 
used to determine the highest drug concentration (H37) 
unable to induce an inhibition of tubulin polymeriza- 
tion (fig.2b). The//37 values, only slightly lower than 
the corresponding H13 values, gave the same order of 
activity (table 1). 
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Table 1 
Characteristic values obtained with the various griseofulvin derivatives 
H:3 H3T MI 4m 4b 
2'-(2qodoethoxy)Griseofulvin 5.8 2.5 1 4 4 
Griseofulvin 18 11 4.5 17 20 
Isogriseofulvin 26 16 38 45 18 
2'-Aminogriseofulvin 360 140 38 200 185 
Griseofulvic acid 1000 290 no effect no effect no effect 
H:3 and H37 are respectively the highest drug concentrations unable to induce protein aggre- 
gation and to inhibit ubulin polymerization. MI is the highest drug concentration which 
does not affect he mitotic index. 4m and 4b are, respectively, the drug concentrations 
which induce the formation of 4% micronuclei and 'budding' nuclei 
3.3. In vivo induced nuclear abnormalities in L1210 
mouse leukemia 
Mouse leukemia was used to study the cytological 
action of griseofulvin derivatives. After adding griseo- 
fulvin an increase of the percentage of mitotic nuclei 
and 2 types of nuclear abnormalities (micronuclei and 
'budding' nuclei) were observed. The mitotic index 
increased with the addition of the various griseofulvin 
derivatives (fig.3a) except with griseofulvic acid. Even 
at the highest concentration (400/aM) of griseofulvic 
acid, the percentage of mitotic nuclei remained nor- 
mal. For the other derivatives the maximum drug 
concentrations (MI) which did not affect the mitotic 
index were 1/aM for 2'(2-iodoethoxy)griseofulvin, 
Fig.3. In vivo effects of griseofulvin derivatives on leukemia 
cells. (a) Mitotic index after 12 h (% nuclei showing condense d 
chromosomes). (b) Micronuclei after 12 h (%). (c) 'Budding' 
nuclei after 24 h (%). In each case, the values observed with 
the controls (3.4-4.2% for mitotic index, 0-15% for micro- 
nuclei and 0-0.3% 'budding' nuclei) have been substracted 
from the percentages obtained on 2000 nuclei. For each 
compound the best curve fitting the experimental values was 
calculated by the method of the least squares. In these xperi- 
ments, the % growth inhibition after 24 h were the following: 
2' (2qodoethoxy) griseofulvin, 2%, 26%, 25%, 48% for 1 pM, 
2.5 pM, 5/~M, 7.5 pM; griseofulvin, 2%, 4%, 28%, 41% for 
7.5 pM, I0 pM, 25 pM, 50 pM; isogriseofulvin, 33%, 59%, 
64%, 69% for 25 pM, 50 ,M, 75 pM, 100 t~M; 2'-aminogriseo- 
fulvin, 3%, 0%, 0%, 7% for 50 pM, 75 pM, 100 pM, 200 t~M; 
griseofulvic acid, 6%, 0%, 0%, 0% for 100 pM, 200 pM, 
300 pM, 400 ,M, respectively. (v) 2'-(2qodoethoxy)griseo- 
fulvin; (o) griseofulvin; (*) isogriseofulvin; (.) 2'-amino- 
griseofulvin; (m) griseofulvie acid. Drug concentrations are
expressed in,M. 
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4.5/aM for griseofulvin and 38/aM for isogriseofulvin 
and 2'-aminogriseofulvin. The same overall picture 
was obtained with the variations of the micronuclei 
or the 'budding' nuclei percentages (fig.3b,c). Griseo- 
fulvic acid was almost completely inactive: less than 
2% micronuclei were produced after 12 h and only 
0.25% 'budding' nuclei after 24 h in the presence of 
the highest available drug concentration (400/aM). In 
order to compare the action of the other compounds 
we have used the drug concentrations leading to 4% 
of micronuclei (4m) and 4% of 'budding' nuclei (4b) 
(table 1). 
3.4. Toxicity on Physarum microplasmodia 
Physarum polycephalum is a Myxomycete sensitive 
to the antifungic action of griseofulvin. Griseofulvin 
specifically disturbed mitotic microtubules leading to 
abnormal nuclei and to a growth arrest after 24 h 
[15]. We found that 2'-(2-iodoethoxy) griseofulvin 
was more potent (10/iM) than griseofulvin (100/aM) 
to inhibit plasmodial growth but 2'-aminogriseofulvin 
and griseofulvic acid were inactive at the highest avail- 
able concentrations (250/aM and 1000/aM, respec- 
tively). 
4. Discussion 
These results indicate that in rive, several deriva- 
tives of griseofulvin are either less active than griseo- 
fulvin, like 2'-aminogriseofulvin a d griseofulvic acid, 
or more active like 2'-(2-iodoethoxy) griseofulvin in 
the case of a Myxomycete and mammalian cells. This 
is in agreement with [16,17] obtained on various 
parasitic fungi. All these compounds induce the same 
nuclear phenotype on mammalian cells which can be 
explained by an action on mitotic microtubules 
[ 18-21 ]. We have found that 2'-(2-iodoethoxy)griseo- 
fulvin, the most active compound in vivo, was also 
the most active in vitro on microtubule protein 
aggregation and on tubulin polymerization. Likewise, 
the 2 less active derivatives in vivo, 2'-(2-aminogriseo- 
fulvin and griseofulvic acid, were found less active 
in vitro. Isogriseofulvin showed in vivo a comparable 
activity with griseofulvin, except in the case of the 
mitotic index, but in vitro was slightly less active than 
griseofulvin. Contrary to what was observed in vitro, 
the slopes of the curves obtained from the in vivo 
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Fig.4. Correlation between in vivo and in vitro effects. Values 
obtained for griseofulvic acid have been omitted because at 
the highest available concentration, this derivative showed no 
increase of the mitotic index and an increase in the percentage 
of micronuclei and 'budding' nuclei lower than 4%. Drug con- 
centrations are expressed in#M. (o,.) H13 and H3~ values 
versus the highest drug concentrations unable to increase the 
mitotic index (/vii); points shown between parentheses 
correspond to isogriseofulvin. (a,A) H a 3 and H,7 values versus 
drug concentrations inducing 4% micronuclei (4m). (w,v) H13 
and H37 values against drug concentrations inducing 4% of 
'budding' nuclei (4b). 
results were different for several compounds. A 
difference in permeation or in metabolization can be 
hypothesized to explain such discrepancies. The order 
of activity of the 5 griseofulvin derivatives found 
in vitro was the same as the order found in rive. The 
probability to find such a distribution is equal to 1/5! 
i.e., 8.4 X 10 -3. 
Thus a correlation seems to exist between the 
in vivo activity of these compounds and their in vitro 
action, both on cold microtubule protein aggregation 
and on tubulin polymerization (rigA). These observa- 
tions strongly support he hypothesis that micro- 
tubule proteins are the pharmacological t rget of 
griseofulvin and of some of its derivatives. This con- 
clusion implies that the different biological activity 
of these compounds i at least partially due to their 
differential effect on the microtubular system. The 
existence of such a correlation suggests also that the 
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in vitro interaction of drugs with microtubule protein 
could be used as a screening procedure in order to 
find more active compounds. 
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